- Conditions
- Healthy Participants
- Interventions
- DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin
- Drug
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–27
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Participants
- Interventions
- AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Diabetes
- Interventions
- Repaglinide and Insulin
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 12 Years to 20 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania